Six years after

Acta Radiologica

Volumn 53, Issue 8, 2012, Pages 827-829

  Thomsen, Henrik S ^a   Bennett, Charles L ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b University of South Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM PENTETATE;

ANIMAL; BONE; CHEMICALLY INDUCED DISORDER; EDITORIAL; HUMAN; METABOLISM; NEPHROGENIC SYSTEMIC FIBROSIS; TIME;

ANIMALS; BONE AND BONES; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; NEPHROGENIC FIBROSING DERMOPATHY; TIME;

EID: 84867700446     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2012.12a005     Document Type: Editorial

References (17)

1. Grobner T. Gadolinium: A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant 2006;21:1104-8
2. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006:17:2359-62 (Pubitemid 44300951)
3. Evans CH, Drouven BJ. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J 1983;213:751-8
4. Evans CH. Biochemistry of the lanthanides. New York, NY: Plenum Press, 1990
5. SMRM workshop on contrast enhanced magnetic resonance. Discussion. Magn Reson Med 1991;22:229-32
6. Muller N, Gunzel P, Schobel C. Ionic and non-ionic gadolinium-containing magnetic resonance contrast media. Comparison of effects and their reversibility in repeated dose toxicity studies in rats. Advances in MRI Contrast 1992;1 (Suppl. 1):15-28
7. Maton F, van der Elst L, Muller RN. Influence of human proteins on the relaxivity of Gd(III) complexes. See http://www.b.dk/upload/webred/bmsandbox/ uploads/2012/03/bb81a28663015b7a1d828ee723de7a26.pdf
8. d828ee723de7a26.pdf 8 Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium based magnetic resonance imaging contrast agents in human serum at 378C. Invest Radiol 2008;43:817-28
9. Bennett CL, Starko KM, Thomsen HS, et al. Linking drugs to obscure illness: Lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. A report from the Southern Network on adverse reactions (SONAR). J Gen Intern Med 2012 Jun 13; doi: 10.1007/s11606-012-2098-1
10. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous disease in renal dialysis patients. Lancet 2000;356:1000-1
11. Giradi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011;65:1095-106
12. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium (III) chelates and MRI agents: Structure, dynamics and applications. Chem Rev 1999;99:2293-352
13. Bennett CL, Qureshi ZP, Sator OA, et al. Gadolinium induced nephrogenic systemic fibrosis, the rise and fall of an iatrogenic disease. Clin Kidney J 2012;5:82-88
14. Pirovano G, Munley J, Schultz C, et al. Nephrogenic systemic fibrosis: A review of published cases and results from three prospective observational studies. ECR 2012;3 (Suppl. 1):S293
15. Amet S, Choukroun G, Launay-Vacher V, et al. Prevalence of nephrogenic systemtic fibrosis in dialysis patients: The Pro-FINEST study. ECR 2012;3 (Suppl. 1):S293
16. Thomsen HS. ESUR guideline: Gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 2007;17:2692-6
17. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-8 (Pubitemid 44406188)